These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 39159497)

  • 1. Rational Design of a Novel 6
    Shi X; Feng H; Tian H; Ma H; Pang X; Mao C; Xiang P; Xu Z; Han W; Yan Y; Chen W; Nan Y; Nan G; Hu Z; Hui L; Li C; Li Y
    J Med Chem; 2024 Sep; 67(17):15387-15410. PubMed ID: 39159497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195).
    Cheng H; Orr STM; Bailey S; Brooun A; Chen P; Deal JG; Deng YL; Edwards MP; Gallego GM; Grodsky N; Huang B; Jalaie M; Kaiser S; Kania RS; Kephart SE; Lafontaine J; Ornelas MA; Pairish M; Planken S; Shen H; Sutton S; Zehnder L; Almaden CD; Bagrodia S; Falk MD; Gukasyan HJ; Ho C; Kang X; Kosa RE; Liu L; Spilker ME; Timofeevski S; Visswanathan R; Wang Z; Meng F; Ren S; Shao L; Xu F; Kath JC
    J Med Chem; 2021 Jan; 64(1):644-661. PubMed ID: 33356246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A deep learning-based theoretical protocol to identify potentially isoform-selective PI3Kα inhibitors.
    Shafiq M; Sherwani ZA; Mushtaq M; Nur-E-Alam M; Ahmad A; Ul-Haq Z
    Mol Divers; 2024 Aug; 28(4):1907-1924. PubMed ID: 38305819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and bioevaluation of dual EGFR-PI3Kα inhibitors for potential treatment of NSCLC.
    Wang T; Wang Y; Lu J; Chen J; Wang L; Ouyang Z; Ouyang W; Hu C; Weng J; Zhang JQ
    Bioorg Chem; 2024 Oct; 151():107714. PubMed ID: 39167867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, Synthesis, Biological Evaluation, and Molecular Modeling of 2-Difluoromethylbenzimidazole Derivatives as Potential PI3Kα Inhibitors.
    Wang X; Zhang M; Zhu R; Wu Z; Wu F; Wang Z; Yu Y
    Molecules; 2022 Jan; 27(2):. PubMed ID: 35056702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 2-(5-(quinolin-6-yl)-1,3,4-oxadiazol-2-yl)acetamide derivatives as novel PI3Kα inhibitors via docking-based virtual screening.
    Gu D; Cheng G; Zhang M; Zhou YB; Li J; Sheng R
    Bioorg Med Chem; 2021 Jan; 29():115863. PubMed ID: 33199203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of novel series of 2H-benzo[b][1,4]oxazin-3(4H)-one and 2H-benzo[b][1,4]oxazine scaffold derivatives as PI3Kα inhibitors.
    Dong FD; Liu DD; Deng CL; Qin XC; Chen K; Wang J; Song HR; Ding HW
    Bioorg Med Chem; 2018 Aug; 26(14):3982-3991. PubMed ID: 29937355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, Synthesis, and Biological Evaluation of Imidazo[1,2-
    Yu Y; Han Y; Zhang F; Gao Z; Zhu T; Dong S; Ma M
    J Med Chem; 2020 Mar; 63(6):3028-3046. PubMed ID: 32069401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a novel aminopyrazine series as selective PI3Kα inhibitors.
    Barlaam B; Cosulich S; Fitzek M; Germain H; Green S; Hanson LL; Harris CS; Hancox U; Hudson K; Lambert-van der Brempt C; Lamorlette M; Magnien F; Ouvry G; Page K; Ruston L; Ward L; Delouvrié B
    Bioorg Med Chem Lett; 2017 Jul; 27(13):3030-3035. PubMed ID: 28526367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based pharmacophore modeling and DFT studies of Indian Ocean-derived red algal compounds as PI3Kα inhibitors.
    Vasuki A; Christy HJ; Renugadevi K; Dammalli M
    Mol Divers; 2024 Aug; 28(4):2563-2581. PubMed ID: 37466805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3Kδ and mTOR dual inhibitors: Design, synthesis and anticancer evaluation of 3-substituted aminomethylquinoline analogues.
    Yevale D; Teraiya N; Lalwani T; Dalasaniya M; Kapadiya K; Ameta RK; Sangani CB; Duan YT
    Bioorg Chem; 2024 Jun; 147():107323. PubMed ID: 38583254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological activity of novel 2,3,4,5-tetra-substituted thiophene derivatives as PI3Kα inhibitors with potent antitumor activity.
    Liao W; Wang Z; Han Y; Qi Y; Liu J; Xie J; Tian Y; Lei Q; Chen R; Sun M; Tang L; Gong G; Zhao Y
    Eur J Med Chem; 2020 Jul; 197():112309. PubMed ID: 32375077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of thieno[3,2-d]pyrimidine derivatives as potential simplified phosphatidylinositol 3-kinase alpha inhibitors.
    Yang X; Deng M; Zhang X; Wang Y; Song K; Cong R; Meng L; Zhang J
    Chem Biol Drug Des; 2019 Dec; 94(6):2013-2022. PubMed ID: 30381889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors.
    Rewcastle GW; Kolekar S; Buchanan CM; Gamage SA; Giddens AC; Tsang KY; Kendall JD; Singh R; Lee WJ; Smith GC; Han W; Matthews DJ; Denny WA; Shepherd PR; Jamieson SMF
    Oncotarget; 2017 Jul; 8(29):47725-47740. PubMed ID: 28537878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a new series of PI3K-δ inhibitors from Virtual Screening.
    Fradera X; Deng Q; Achab A; Garcia Y; Kattar SD; McGowan MA; Methot JL; Wilson K; Zhou H; Shaffer L; Goldenblatt P; Tong V; Augustin MA; Altman MD; Lesburg CA; Shah S; Katz JD
    Bioorg Med Chem Lett; 2021 Jun; 42():128046. PubMed ID: 33865969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and Optimization of Pyridazinones as PI3Kδ Selective Inhibitors for Administration by Inhalation.
    Bruno P; Micoli A; Corsi M; Pala D; Guariento S; Fiorelli C; Ronchi P; Fioni A; Gallo PM; Marenghi G; Bertolini S; Capacchi S; Mileo V; Biagetti M; Capelli AM
    J Med Chem; 2024 Jul; 67(13):11103-11124. PubMed ID: 38907711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).
    Heffron TP; Heald RA; Ndubaku C; Wei B; Augistin M; Do S; Edgar K; Eigenbrot C; Friedman L; Gancia E; Jackson PS; Jones G; Kolesnikov A; Lee LB; Lesnick JD; Lewis C; McLean N; Mörtl M; Nonomiya J; Pang J; Price S; Prior WW; Salphati L; Sideris S; Staben ST; Steinbacher S; Tsui V; Wallin J; Sampath D; Olivero AG
    J Med Chem; 2016 Feb; 59(3):985-1002. PubMed ID: 26741947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K/mTOR inhibitors.
    Wu TT; Guo QQ; Chen ZL; Wang LL; Du Y; Chen R; Mao YH; Yang SG; Huang J; Wang JT; Wang L; Tang L; Zhang JQ
    Eur J Med Chem; 2020 Oct; 204():112637. PubMed ID: 32717477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Pyrazolo[1,5-
    Wang C; Zou F; Qi Z; Liu Q; Shen L; Yuan X; Deng M; Wang A; Wang B; Wang L; Liang X; Liu Q; Liu J
    J Med Chem; 2024 Sep; 67(17):15199-15219. PubMed ID: 39163191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-Phenyl-4-hydroxy-2-quinolone-3-carboxamides as selective inhibitors of mutant H1047R phosphoinositide-3-kinase (PI3Kα).
    Sabbah DA; Simms NA; Wang W; Dong Y; Ezell EL; Brattain MG; Vennerstrom JL; Zhong HA
    Bioorg Med Chem; 2012 Dec; 20(24):7175-83. PubMed ID: 23121722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.